|
業務類別
|
Biotechnology |
|
業務概覽
|
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin. |
| 公司地址
| 19 Vestry Street, New York, NY, USA, 10013 |
| 電話號碼
| +1 647 865-8622 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.brightmindsbio.com |
| 員工數量
| 1 |
| Mr. Ryan E. Cheung, C.A.,C.P.A. |
Chief Financial Officer and Corporate Secretary |
-- |
23/12/2025 |
| Mr. Ian McDonald |
President, Chief Executive Officer and Director |
-- |
23/12/2025 |
| Dr. Jan Pedersen, PhD |
Director and Chief Science Officer |
-- |
23/12/2025 |
| Dr. Stephen D. Collins |
Chief Medical Officer |
-- |
23/12/2025 |
| Mr. Alex Vasilkevich, M.Sc. |
Chief Operating Officer and Senior Strategic Officer |
-- |
23/12/2025 |
|
|
| Dr. David M. Weiner, M.D. |
Independent Director |
23/12/2025 |
| Mr. Ian McDonald |
President, Chief Executive Officer and Director |
23/12/2025 |
| Mr. Nils Christian Bottler |
Independent Director |
23/12/2025 |
| Mr. Jeremy Fryzuk |
Independent Director |
23/12/2025 |
| Dr. Jan Pedersen, PhD |
Director and Chief Science Officer |
23/12/2025 |
|
|
|
|
